Patents by Inventor Alexander J. Pallenberg
Alexander J. Pallenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8822677Abstract: An improved two stage reaction process for production of mono-L-aspartyl chlorin e6. In a first stage, the activation reaction between chlorin e6 and a carbodiimide produces a previously unknown anhydride in an activation reaction product (Formula I). This reaction product is purified to remove a significant proportion of the precursors of di-L-aspartyl chlorin e6. The purified activation reaction product contains a higher concentration of the previously unknown anhydride. This purified reaction product is used in a second stage: a coupling reaction of the purified activation reaction product with aspartate. The coupling reaction produces a coupling reaction product that has significantly reduced di-L-aspartyl chlorin e6 concentration. This reduced di-L-aspartyl chlorin e6 concentration facilitates purification of mono-L-aspartyl chlorin e6 from the coupling reaction mixture.Type: GrantFiled: May 16, 2012Date of Patent: September 2, 2014Assignee: Purdue Pharmaceutical Products L.P.Inventors: Leon Xu, Alexander J. Pallenberg
-
Publication number: 20130281689Abstract: An improved two stage reaction process for production of mono-L-aspartyl chlorin e6. In a first stage, the activation reaction between chlorin e6 and a carbodiimide produces a previously unknown anhydride in an activation reaction product. This reaction product is purified to remove a significant proportion of the precursors of di-L-aspartyl chlorin e6. The purified activation reaction product contains a higher concentration of the previously unknown anhydride. This purified reaction product is used in a second stage: a coupling reaction of the purified activation reaction product with aspartate. The coupling reaction produces a coupling reaction product that has significantly reduced di-L-aspartyl chlorin e6 concentration. This reduced di-L-aspartyl chlorin e6 concentration facilitates purification of mono-L-aspartyl chlorin e6 from the coupling reaction mixture.Type: ApplicationFiled: May 16, 2012Publication date: October 24, 2013Inventors: Leon Xu, Alexander J. Pallenberg
-
Patent number: 8198312Abstract: A composition of matter of an anhydride of formula 1 below and an improved two stage reaction process for production of mono-L-aspartyl chlorin e6, utilizing the anhydride:Type: GrantFiled: June 29, 2007Date of Patent: June 12, 2012Assignee: Light Sciences Oncology, Inc.Inventors: Leon Xu, Alexander J. Pallenberg
-
Patent number: 8063203Abstract: An improved two stage reaction process for production of mono-L-aspartyl chlorin e6. In a first stage, the activation reaction between chlorin e6 and a carbodiimide produces a previously unknown anhydride in an activation reaction product. This reaction product is purified to remove a significant proportion of the precursors of di-L-aspartyl chlorin e6. The purified activation reaction product contains a higher concentration of the previously unknown anhydride. This purified reaction product is used in a second stage: a coupling reaction of the purified activation reaction product with aspartate. The coupling reaction produces a coupling reaction product that has significantly reduced di-L-aspartyl chlorin e6 concentration. This reduced di-L-aspartyl chlorin e6 concentration facilitates purification of mono-L-aspartyl chlorin e6 from the coupling reaction mixture.Type: GrantFiled: November 1, 2010Date of Patent: November 22, 2011Assignee: Light Sciences Oncology, Inc.Inventors: Leon Xu, Alexander J. Pallenberg
-
Publication number: 20110105745Abstract: An improved two stage reaction process for production of mono-L-aspartyl chlorin e6. In a first stage, the activation reaction between chlorin e6 and a carbodiimide produces a previously unknown anhydride in an activation reaction product. This reaction product is purified to remove a significant proportion of the precursors of di-L-aspartyl chlorin e6. The purified activation reaction product contains a higher concentration of the previously unknown anhydride. This purified reaction product is used in a second stage: a coupling reaction of the purified activation reaction product with aspartate. The coupling reaction produces a coupling reaction product that has significantly reduced di-L-aspartyl chlorin e6 concentration. This reduced di-L-aspartyl chlorin e6 concentration facilitates purification of mono-L-aspartyl chlorin e6 from the coupling reaction mixture.Type: ApplicationFiled: November 1, 2010Publication date: May 5, 2011Applicant: Light Sciences Oncology, Inc.Inventors: Leon Xu, Alexander J. Pallenberg
-
Publication number: 20090118816Abstract: A treatment system to provide energy therapy to a patient includes an implantable device and an activation system having a plurality of energy emitters that transmit energy towards the device. In one embodiment, the implantable device is a stent carrying a treatment agent. The treatment agent can be selectively activated by the activation system before, during, or after implantation in a subject's body. The activated treatment agent can react with adjacent tissues.Type: ApplicationFiled: September 5, 2006Publication date: May 7, 2009Inventors: Nicholas Kipshidze, Gary Lichttenegger, Alexander J. Pallenberg, Nick Yeo, Thomas L. Wenger
-
Patent number: 7053210Abstract: A process for the preparation of pyropheophorbide a and its derivatives, including 3-devinyl-3-(1?-hexyloxy)ethyl-pyropheophorbide-a, otherwise known as HPPH, is provided. The process involves treating chlorin e6, in the form of its trimethyl ester, with a base, followed by heating to give pyropheophorbide a, which is converted to HPPH by treatment with acid, followed by hexyl alcohol under basic conditions.Type: GrantFiled: July 2, 2003Date of Patent: May 30, 2006Assignee: Health Research, Inc.Inventors: Ravindra K. Pandey, Thomas J. Dougherty, Alexander J. Pallenberg
-
Publication number: 20040044198Abstract: A process for the preparation of pyropheophorbide a and its derivatives, including 3-devinyl-3-(1′-hexyloxy)ethyl-pyropheophorbide-a, otherwise known as HPPH, is provided. The process involves treating chlorin e6, in the form of its trimethyl ester, with a base, followed by heating to give pyropheophorbide a, which is converted to HPPH by treatment with acid, followed by hexyl alcohol under basic conditions.Type: ApplicationFiled: July 2, 2003Publication date: March 4, 2004Inventors: Ravindra K. Pandey, Thomas J. Dougherty, Alexander J. Pallenberg
-
Patent number: 6017888Abstract: Peptide-copper complexes are disclosed which stimulate the growth of hair on warm-blooded animals. In one aspect of this invention, the peptide-copper complexes are dipeptides or tripeptides chelated to copper at a molar ratio ranging from about 1:1 to 3:1, with the second position of the peptide from the amino terminus being histidine, arginine or a derivative thereof. The peptide-copper complexes may be formulated for administration by, for example, topical application or injection. Any affliction associate with hair loss, including hair loss associated with both androgenetic and secondary alopecia, may be treated with the peptide-copper complexes of this invention.Type: GrantFiled: December 23, 1997Date of Patent: January 25, 2000Assignee: ProCyte CorporationInventors: Alexander J. Pallenberg, Leonard M. Patt, Ronald E. Trachy
-
Patent number: 5637311Abstract: Zinc(II) complexes and methods relating thereto are disclosed. The zinc(II) complexes comprise a zinc(II) ion complexed by a multi-dentate ligand. Methods of this invention include the use of the zinc(II) complexes as anti-viral agents and/or as anti-inflammatory agents. Methods of this invention also include inhibition of viral infection, as well as inhibiting transmission of sexually transmitted diseases. Exemplary zinc(II) complexes include zinc(II):neocuproine (2:1) and zinc(II):bathocuproine disulfonic acid (2:1).Type: GrantFiled: June 29, 1995Date of Patent: June 10, 1997Assignee: ProCyte CorporationInventor: Alexander J. Pallenberg
-
Patent number: 5538945Abstract: Peptide-copper complexes are disclosed which stimulate the growth of hair on warm-blooded animals. In one aspect of this invention, the peptide-copper complexes are dipeptides or tripeptides chelated to copper at a molar ratio ranging from about 1:1 to 3:1, with the second position of the peptide from the amino terminus being histidine, arginine or a derivative thereof. The peptide-copper complexes may be formulated for administration by, for example, topical application or injection. Any affliction associate with hair loss, including hair loss associated with both androgenetic and secondary alopecia, may be treated with the peptide-copper complexes of this invention.Type: GrantFiled: June 17, 1994Date of Patent: July 23, 1996Assignee: ProCyte CorporationInventors: Alexander J. Pallenberg, Leonard M. Patt, Ronald E. Trachy